著者
Liying Dong Shasha Hu Jianjun Gao
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.14, no.1, pp.58-60, 2020-02-29 (Released:2020-03-08)
参考文献数
19
被引用文献数
718

The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.
著者
Masashi Ohe Ken Furuya Houman Goudarzi
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2021.01005, (Released:2021-02-19)
参考文献数
25
被引用文献数
2

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is a process of identifying new therapeutic uses for approved drugs. It is an effective strategy to discover drug molecules with new therapeutic indications. This strategy is time-saving, low-cost, and has a minimal risk of failure. Several existing approved drugs such as chloroquine, hydroxychloroquine, doxycycline, azithromycin, and ivermectin are currently in use because of their efficacy in inhibiting COVID-19. Multidrug therapy, such as a combination of hydroxychloroquine and azithromycin, a combination of doxycycline and ivermectin, or a combination of ivermectin, doxycycline, and azithromycin, has been successfully administered. Multidrug therapy is efficacious because the mechanisms of action of these drugs differ. Moreover, multidrug therapy may prevent the emergence of drug-resistant SARS-CoV-2.
著者
Masashi Ohe Ken Furuya Houman Goudarzi
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.15, no.1, pp.39-41, 2021-02-28 (Released:2021-03-10)
参考文献数
25
被引用文献数
1 2

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is a process of identifying new therapeutic uses for approved drugs. It is an effective strategy to discover drug molecules with new therapeutic indications. This strategy is time-saving, low-cost, and has a minimal risk of failure. Several existing approved drugs such as chloroquine, hydroxychloroquine, doxycycline, azithromycin, and ivermectin are currently in use because of their efficacy in inhibiting COVID-19. Multidrug therapy, such as a combination of hydroxychloroquine and azithromycin, a combination of doxycycline and ivermectin, or a combination of ivermectin, doxycycline, and azithromycin, has been successfully administered. Multidrug therapy is efficacious because the mechanisms of action of these drugs differ. Moreover, multidrug therapy may prevent the emergence of drug-resistant SARS-CoV-2.
著者
Itsuro Kazama
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2020.03095, (Released:2020-10-29)
参考文献数
30
被引用文献数
9

Regardless of the severity of coronavirus disease 2019 (COVID-19), a high proportion of patients struggle with persistent respiratory or systemic symptoms after recovery. This is called "postCOVID syndrome", for which pulmonary fibrosis is one of the pathogenesis. Besides T-lymphocytes and macrophages, mast cells also contribute to the development of cytokine storm and thus stimulate the activity of fibroblasts. Additionally, by the exocytotic release of fibroblast-activating factors, mast cells directly facilitate the progression of pulmonary fibrosis. In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed their potency as highly effective mast cell stabilizers. Given such pharmacological properties of these commonly used drugs, they may be useful in the treatment of post-COVID-19 pulmonary fibrosis and in relieving the symptoms of post-COVID syndrome.
著者
Yuko Wada Maki Kihara Mitsuru Nozawa Ken-ichi Shimokawa Fumiyoshi Ishii
出版者
バイオ&ソーシャル・サイエンス推進国際研究交流会
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.9, no.3, pp.229-233, 2015 (Released:2015-07-17)
参考文献数
11
被引用文献数
11

The physicochemical and pharmaceutical properties (pH, peel force, water-vapor permeability, and stretchability) of brand-name and generic ketoprofen products were evaluated and compared. The pHs of Mohrus as a brand-name product and Teikoku as a generic product were low (about 4). Among the other generic products, Patell and Nichi-Iko had a pH of about 4.3 while Frestol, Raynanon, BMD, and Touchron showed a pH of 4.6-5.2, which was in the pH range of normal healthy skin (4.5-6.5). The adhesive force was high (≥ 1.38) for Mohrus as a brand-name product as well as for Teikoku and Patell as generic products, but it was low (≤ 0.57) for the other 5 generic products. The water-vapor permeabilities of Mohrus as a brand-name product and Teikoku and Patell as generic products were low, being less than 1/6 of those for the other 5 generic products. Among the 5 generic products, BMD showed the highest water-vapor permeability (1,330 g/m2), and the other products also showed a value ≥ 1,100 g/m2. The elongatedness of Mohrus was the lowest (15.5 cm), and that of Raynanon was the highest (24.5 cm); the difference was 9 cm. In this study, the physiochemical and pharmaceutical properties of ketoprofen tapes were clarified, which will allow pharmacists to provide products according to the needs of each patient when a brand-name product is changed to a generic one.
著者
Fangyuan Shi Zongtao Li Lingjin Kong Yuanchao Xie Tao Zhang Wenfang Xu
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.8, no.3, pp.117-120, 2014-06-30 (Released:2014-07-17)
参考文献数
10
被引用文献数
4 20

As a RNA polymerase inhibitor, 6-fluoro-3-hydroxypyrazine-2-carboxamide commercially named favipiravir has been proved to have potent inhibitory activity against RNA viruses in vitro and in vivo. A four-step synthesis of the compound is described in this article, amidation, nitrification, reduction and fluorination with an overall yield of about 8%. In addition, we reported the crystal structure of the title compound. The molecule is almost planar and the intramolecular O−H•••O hydrogen bond makes a 6-member ring. In the crystal, molecules are packing governed by both hydrogen bonds and stacking interactions.
著者
Maki K. Yamada
出版者
バイオ&ソーシャル・サイエンス推進国際研究交流会
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.10, no.2, pp.79-81, 2016 (Released:2016-05-23)
参考文献数
35
被引用文献数
2

Whole brain radiation therapy for the treatment of tumors can sometimes cause cognitive impairment. Memory deficits were noted in up to 50% of treated patients over a short period of several months. In addition, an increased rate of dementia in young patients has been noted over the longer term, i.e. years. A deficit in neurogenesis after irradiation has been postulated to be the main cause of cognitive decline in patients, but recent data on irradiation therapy for limited parts of the brain appear to indicate other possibilities. Irradiation can directly damage various types of cells other than neuronal stem cells. However, this paper will focus on injury to brain vasculature leading to cognitive decline since vessels represent a better therapeutic target for drug development than other cells in the brain because of the blood-brain barrier.
著者
Anivita Aggarwal Ankit Mittal Manish Soneja Sujay Halkur Shankar Shivdas Naik Parul Kodan Neeraj Nischal Pankaj Jorwal Animesh Ray Naveet Wig
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2021.01081, (Released:2021-10-28)
参考文献数
13

Use of systemic corticosteroids is well-established in COVID-19 patients with hypoxia; however, there is scant data on its role in patients with mild disease and prolonged symptoms as a measure to prevent disease progression. The aim of this study is to evaluate the role of systemic corticosteroids in preventing hypoxia (SpO2 ≤ 93% on room-air) among mild COVID-19 patients. An observational study was conducted among symptomatic COVID-19 patients taking oral corticosteroids and attending institute teleconsultation facility between 10th-30th June 2021. Patients who were already on corticosteroids for other indication or required oxygen supplementation before or within 24-hours of initiation of corticosteroids were excluded. A total of 140 consecutive symptomatic COVID-19 patients were included. Higher baseline C-reactive protein (OR: 1.03, 95% CI: 1.02-1.06, p < 0.001) and early systemic corticosteroid (within 7 days) initiation (OR: 6.5, 95% CI: 2.1-20.1, p = 0.001) were independent risk factors for developing hypoxia (SpO2 ≤ 93%). Progression to hypoxia was significantly higher in patients who received corticosteroids before day 7 of illness (36.7%, 95% CI, 23.4-51.7%) compared to ≥ 7 of illness (14.3%, 95% CI, 7.8-23.2%) for persistent fever. Systemic corticosteroids within 7 days from symptom-onset were harmful and increased the risk of progression to hypoxia, whereas it may decrease the risk of progression when administered on or beyond 7 days in patients with mild COVID-19 and persistent symptoms. A well-designed randomised controlled trial is required to validate the findings.
著者
Nihal Ali Nitin Gupta Kavitha Saravu
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.14, no.3, pp.135-138, 2020-06-30 (Released:2020-07-15)
参考文献数
12
被引用文献数
1

Drug-induced liver injury (DILI) due to anti-tubercular treatment (ATT) leads to increased morbidity and mortality in patients with tuberculosis (TB). The aim of this study was to find the impact of malnutrition on the development of DILI. This was a prospective cohort study (September 2017 to August 2019) in which all newly diagnosed in-patients with tuberculosis above the age of 18 years were included. Those patients with a body mass index (BMI) of < 18.5 kg/m2 were considered malnourished. The patients were monitored for the development of DILI. Liver function tests were done at the baseline (before initiation of ATT), on the third day and at discharge in all the patients. Chi-square tests and conditional multiple logistic analysis was performed to identify risk factors associated with DILI. Out of the 319 subjects who were enrolled, a total of 138 patents chose to follow up at our hospital. A total of 14 patients (10%) developed DILI. The median time to onset of DILI was found to be ten days. Extra-pulmonary TB, low BMI and high baseline liver enzyme levels had a significant association with the development of DILI (p < 0.05). Low serum albumin had increased odds ratio but wasn't statistically significant. Malnutrition is an important risk factor for TB-DILI.
著者
Yuko Wada Yukie Takaoka Mitsuru Nozawa Miho Goto Ken-ichi Shimokawa Fumiyoshi Ishii
出版者
バイオ&ソーシャル・サイエンス推進国際研究交流会
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2016.01053, (Released:2016-10-04)
参考文献数
16
被引用文献数
4

We measured the pH, water-vapor permeability, adhesive force, peeling-force, elongation rate, support flexibility, and peeling time of medicinal and over-the-counter (OTC) tape preparations containing felbinac. When measuring the pH of each preparation, Felnabion (pH 4.5) was weakly acidic, and EMEC and Tokuon (pH 7.0) were neutral. When measuring the water-vapor permeability of each preparation, that of a generic product, EMEC (380 g/m2/24h), was twice as high as that of a brand-name product, Seltouch (189 g/m2/24 h). The adhesive force was measured using the ball tack test. The adhesive forces of OTC drugs, Salomethyl, Homepass, and Tokuhon (1.04 g), were higher than that of Seltouch (0.06 g). Concerning peeling-force measurement, the peeling-forces of a generic product, Falzy (4.15 N), and an OTC drug, Omuneed (4.89 N), were higher than that of Seltouch (0.91 N). The elongation rates of a generic product, Sumilu (319%), and OTC drugs, Nabolin (298%) and Homepass (299%), were higher than that of Seltouch (251%), but that of Tokuhon (72%) was lower. The support flexibilities of EMEC (150 degrees) and Tokuhon (131 degrees) were higher than that of Seltouch (96 degrees). In addition, the peeling time of Seltouch was 120 min or more, whereas those of EMEC and Nabolin were 1.4 and 0.2 min, respectively. These results suggest that the differences in pharmaceutical properties, such as the pH, water-vapor permeability, adhesive force, peeling-force, elongation rate, support flexibility, and peeling time, among the preparations markedly influence patients' subjective comfortableness. The results of this study facilitated individuals’ comfortableness-matched drug selection.
著者
Yusaku Matsumoto Hayato Kizaki Yuki Ikeda Shohei Nakamura Shinya Kina Takanori Nagai Takafumi Nasu Koji Miyamoto Satoko Hori
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2021.01102, (Released:2021-12-30)
参考文献数
7

Japan has an ageing population and geographical impediments to healthcare access, so an experimental trial of telepharmacy has recently been implemented in remote islands or remote areas of Japan prior to the formal implementation. This exploratory study was conducted to understand patients’ perspectives on telepharmacy in a mountainous depopulated area away from urban areas of Japan. Semi-structured interviews were conducted with four elderly patients, who were all of the patients receiving telepharmacy in Toyone village, Japan, at the time of the survey. The transcribed interview data were qualitatively analyzed by coding and categorization. The subjects thought telepharmacy would be advantageous to overcome poor access to a clinic and to improve convenience in processes ranging from medical examination to obtaining prescribed medicines. However, they pointed out the low digital literacy of the elderly. Also, they had low expectations for pharmacists, because they had previously had no relationship with pharmacists due to lack of pharmacies in the area. To promote telepharmacy, efforts to eliminate resistance to smartphones and to provide support for smartphone operations are needed among the elderly. Work is also needed to establish how pharmacists should best be involved in patient care and health support in remote areas. Our findings suggest that telepharmacy is useful in remote areas of Japan, but in locations where there is no existing relationship with pharmacists, it would be desirable for pharmacists to be actively involved with the community to maximize its effectiveness.
著者
Talakola Naveen Ashutosh Biswas Naveet Wig Manish Soneja Pankaj Jorwal Chitikela Sindhura Durga Paras Singla Charusmita Chaudhary Upendra Baitha
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.13, no.1, pp.59-61, 2019-02-28 (Released:2019-03-16)
参考文献数
7

Familial hypercholesterolemia (FH) is a form of primary hyperlipoproteinemia characterized by the presence of high concentrations of serum low density lipoprotein (LDL) cholesterol, increased tendency to form xanthomas and early onset of coronary artery disease. This disease is an autosomal dominant disorder caused by defects in the gene that encode for the LDL receptor. Homozygous familial hypercholesterolemia is a rare occurrence and here we report a case of an 18-year-old girl with familial hypercholesterolemia treated with anti-lipidemic drugs and controlled only with LDL apheresis. The patient expired after 3 months highlighting the difficulties in management due to economic constraints in a resource limited setting in spite of availability of effective therapy.
著者
Hiroko Tabunoki Hidemasa Bono Katsuhiko Ito Takeshi Yokoyama
出版者
バイオ&ソーシャル・サイエンス推進国際研究交流会
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2016.01011, (Released:2016-02-07)
参考文献数
48
被引用文献数
1 15

Bombyx mori (silkworm) is the most famous lepidopteran in Japan. B. mori has long been used in the silk industry and also as a model insect for agricultural research. In recent years, B. mori has attracted interest in its potential for use in pathological analysis of model animals. For example, the human macular carotenoid transporter was discovered using information of B. mori carotenoid transporter derived from yellow-cocoon strain. The B. mori carotenoid transport system is useful in human studies. To develop a human disease model, we characterized the human homologs of B. mori, and by constructing KAIKO functional annotation pipeline, and to analyze gene expression profile of a unique B. mori mutant strain using microarray analysis. As a result, we identified a novel molecular network involved in Parkinson's disease. Here we describe the potential use of a spontaneous mutant silkworm strain as a human disease model. We also summarize recent progress in the application of genomic information for annotation of human homologs in B. mori. The B. mori mutant will provide a clue to pathological mechanisms, and the findings will be helpful for the development of therapies and for medical drug discovery.
著者
Jianjun Gao Lin Yin
出版者
バイオ&ソーシャル・サイエンス推進国際研究交流会
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.8, no.5, pp.229-231, 2014-10-31 (Released:2014-11-08)
参考文献数
16
被引用文献数
5 13

The Ebola outbreak in West Africa this year is causing global panic. The high mortality of this disease is largely due to lack of effective preventive vaccines or therapeutic drugs. Realizing the gravity and urgency in controlling the epidemic, governments and drug companies across the world have taken many strong measures to speed up the process of drug development. Several representative candidate drugs that demonstrate potent anti-Ebola activity in preclinical studies have been pushed forward to higher research stages to obtain an earlier official license. It is expected that proven preventive or therapeutic regimens could be established in the near future.
著者
Surachai Ngamratanapaiboon Pracha Yambangyang
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.15, no.6, pp.317-324, 2021-12-31 (Released:2022-01-15)
参考文献数
30

Most studies of antipsychotic-therapies have highlighted the discrepancy between plasma and brain pharmacokinetics of antipsychotics, but how the drug changes through the blood brain barrier (BBB) has not been investigated. Cell-based metabolomics using liquid chromatography-mass spectrometry (LC-MS) combined with multivariate data analysis were applied for screening of antipsychotic metabolites in the BBB. We applied this approach to analyze the antipsychotic biotransformation in brain microvascular endothelia cells (BMVECs), the main component of the BBB. From this study, five, four, three, and one metabolite of chlorpromazine, clozapine, haloperidol and risperidone, respectively, were locally metabolized on the BMVECs. These results confirm that there is a drug biotransformation process within the BBB and show that drug metabolite screening employed cell-based metabolomics using LC-MS, combined with multivariate analysis in the study of BMVECs exposed to antipsychotics can provide a way to screen drug metabolites in the BBB.
著者
Shivdas Naik Soumendra Nath Haldar Manish Soneja Netto George Mundadan Prerna Garg Ankit Mittal Devashish Desai Praveen Kumar Trilangi Sayan Chakraborty Nazneen Nahar Begam Bisakh Bhattacharya Ganesh Maher Niranjan Mahishi Chaithra Rajanna Swasthi S Kumar Bharathi Arunan J Kirtana Ankesh Gupta Diksha Patidar Parul Kodan Prayas Sethi Animesh Ray Pankaj Jorwal Arvind Kumar Neeraj Nischal Sanjeev Sinha Ashutosh Biswas Naveet Wig
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2021.01093, (Released:2021-10-30)
参考文献数
26
被引用文献数
1

Post COVID-19 sequelae are a constellation of symptoms often reported after recovering from COVID-19. There is a need to better understand the clinical spectrum and long-term course of this clinical entity. The aim of this study is to describe the clinical features and risk factors of post COVID-19 sequelae in the North Indian population. This prospective observational study was conducted at a tertiary healthcare centre in Northern India between October 2020 and February 2021. Patients aged >18 years with laboratory-confirmed COVID-19 were recruited after at least two weeks of diagnosis, and details were captured. A total of 1234 patients were recruited and followed up for a median duration of 91 days (IQR: 45-181 days). Among them, 495 (40.1%) had persistent symptoms post-discharge or recovery. In 223 (18.1%) patients, the symptoms resolved within four weeks; 150 (12.1%) patients had symptoms till 12 weeks, and 122 (9.9%) patients had symptoms beyond 12 weeks of diagnosis/symptom-onset of COVID-19. Most common symptoms included myalgia (10.9%), fatigue (5.5%), shortness of breath (6.1%), cough (2.1%), insomnia (1.4%), mood disturbances (0.48%) and anxiety (0.6%). Patients who were hospitalized were more likely to report fatigue as a feature of long COVID. Hypothyroidism (OR: 4.13, 95% CI: 2.2-7.6, p-value < 0.001) and hypoxia (SpO2 ≤ 93%) (OR: 1.7, 95% CI: 1.1-2.4, p-value 0.012) were identified as risk factors for long COVID sequelae. In conclusion, long COVID symptoms were common (22%), and 9.9% had the post COVID-19 syndrome. Myalgias, fatigue and dyspnoea were common symptoms. Patients with hypothyroidism and hypoxia during acute illness were at higher risk of long COVID.
著者
Itsuro Kazama
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2020.03046, (Released:2020-06-25)
参考文献数
18
被引用文献数
3 6

In the midst of a pandemic, finding effective treatments for coronavirus disease 2019 (COVID-19) is the urgent issue. In "chronic inflammatory diseases", the overexpression of delayed rectifier K+-channels (Kv1.3) in leukocytes is responsible for the overactivation of cellular immunity and the subsequent cytokine storm. In our previous basic studies, drugs including chloroquine and azithromycin strongly suppressed the channel activity and pro-inflammatory cytokine production from lymphocytes. These findings suggest a novel pharmacological mechanism by which chloroquine, with or without azithromycin, is effective for severe cases of COVID-19, in which the overactivation of cellular immunity and the subsequent cytokine storm are responsible for the pathogenesis.
著者
Waquar Ahsan Shamama Javed Mohammed Al Bratty Hassan A. Alhazmi Asim Najmi
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
pp.2020.03008, (Released:2020-04-25)
参考文献数
38
被引用文献数
15

The virus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is currently affecting more than 200 countries and territories worldwide. It has been declared as pandemic by World Health Organization (WHO) and the whole world is suffering from corona virus disease 2019 (COVID-19). Currently, no treatment for SARS-CoV-2 are approved because of lack of evidence, but a number of clinical trials are in process and we are expecting fruitful results very soon. This review focuses on various approaches of treatment and few of the most recent clinical trials carried out in this field.
著者
Yuya Kawano Katsunari Makino Masatoshi Jinnin Soichiro Sawamura Shuichi Shimada Satoshi Fukushima Hironobu Ihn
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.13, no.5, pp.268-273, 2019-10-31 (Released:2019-11-14)
参考文献数
17

Although royal jelly is believed to prevent skin aging, the underlying mechanism is not known in detail. In the present study, we investigated the plausibility of the involvement of microRNAs in the manifestation of this effect of royal jelly. The expression of microRNAs was determined by PCR array analysis and real-time PCR and the number of cells was counted with a cell counter. Using PCR array, we identified four microRNAs that were downregulated by royal jelly in cultured human dermal microvascular endothelial cells (HDMEC). Upon comparison of the expression of the four microRNAs between young and senescent facial skin, miR-129-5p was found to be significantly upregulated in senescent skin. Consistently, the expression of miR-129-5p in HDMEC was significantly increased by UVB radiation, suggesting that this microRNA is related to photoaging. The royal jelly treatment increased the number of HDMEC. Furthermore, forced overexpression of miR-129-5p resulted in significant decrease in the number of HDMEC, and its forced downregulation increased the number of cells. The number and density of vessels is reported to be decreased in aged skin. Our results indicate that miR-129-5p is induced in damaged endothelial cells upon exposure to UV radiation, which decreases the cell number. Furthermore, administration of royal jelly downregulated the expression of miR-129-5p in endothelial cells, and might prevent skin aging by maintaining the number of cells. The present study elucidates the mechanism of vessel aging caused by UV exposure and the anti-aging effects of royal jelly through the involvement of microRNA.
著者
Kei Kikuchi Akiko Miki Hiroki Satoh Noriko Iba Rika Sato-Sakuma Hirokuni Beppu Yasufumi Sawada
出版者
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
雑誌
Drug Discoveries & Therapeutics (ISSN:18817831)
巻号頁・発行日
vol.13, no.4, pp.183-188, 2019-08-31 (Released:2019-09-18)
参考文献数
13

Patient narratives of adverse drug events (ADEs) often differ from the symptoms listed on the package inserts of pharmaceutical products using common ADE terminology and could be a source of great comfort to patients with the same disease. To explore this idea, we analyzed written narratives obtained from 48 patients with breast cancer using the NPO Corporation Database of Individual Patients' Experiences, Japan (DIPEx-Japan). Our analysis aimed to determine the utility of an "Adverse Drug Event Database" for use in clinical settings as a novel source of disease information in patients' own words. An analysis of transcripts from 29 patients, in which they recounted their treatment drugs and the time of onset and duration of ADEs in great detail, revealed several discrepancies between the language they used to describe various side effects and the standard ADE terminology on package inserts. We conclude that the language used to describe ADEs on package inserts is insufficient for helping patients as they struggle to recognize, internalize, and overcome ADEs, and argue the need for available, detailed information in the words of real patients about the nature of the ADEs predicted, as well as their clinical course and duration. Such information would be invaluable in supplementing the standardized language used on package inserts. Databases of patients' narrative accounts of ADEs are needed as information sources that can be reliably disseminated among patients.